RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma.

This study was performed to determine whether epigenetic aberrant methylation of RASSF1A might be associated with hepatocarcinogenesis. Methylation specific-PCR was performed to identify RASSF1A promoter hypermethylation in 29 tumors and corresponding normal liver tissues. In addition, RASSF1A mRNA levels were analyzed by quantitative real-time reverse transcription-PCR. Aberrant methylation of RASSF1A was detected in 25 of 29 cases (86%), with loss of RASSF1A expression evident in 8 of 22 cases (36%). No correlation between loss of RASSF1A mRNA and promoter hypermethylation of the RASSF1A gene was observed. There was a significant correlation between the methylation status of RASSF1A and hepatocellular carcinoma (HCC) patients who did not undergo chemotherapy (P = 0.03). Multivariate analysis, adjusted for tumor size, treatment, RASSF1A hypermethylation, and RASSF1A under-expression, showed RASSF1A hypermethylation to be assocaited with a better prognosis for HCC patients (HR= 0.089, 95%CI = 0.013-0.578; P = 0.012). Our findings showed that RASSF1A promoter hypermethylation occurs frequently, and may serve as a good prognostic factor.

[1]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[2]  Diane D. Liu,et al.  Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[3]  Y. Shim,et al.  Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. , 2003, Cancer research.

[4]  Y. Wang,et al.  Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[5]  J. Herman,et al.  Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. , 2003, The American journal of pathology.

[6]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[7]  W. Yeo,et al.  High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[8]  M. Toyota,et al.  Detection of hypermethylation of thep16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus , 2001, Gut.

[9]  M. Washington,et al.  M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity , 1995, Nature Genetics.

[10]  M. Ozturk,et al.  Smad2 and Smad4 gene mutations in hepatocellular carcinoma , 1999, Oncogene.

[11]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[12]  Takafumi Yoshida,et al.  SOCS1 Is a Suppressor of Liver Fibrosis and Hepatitis-induced Carcinogenesis , 2004, The Journal of experimental medicine.

[13]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[14]  C. Croce,et al.  Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. Hirohashi,et al.  Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. , 1994, Cancer research.

[16]  M. Kew,et al.  β‐catenin mutations and expression, 249serine p53 tumor suppressor gene mutation, and hepatitis B virus infection in southern African Blacks with hepatocellular carcinoma , 2005 .

[17]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[18]  Marius Žemaitis,et al.  Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. , 2007, Lung cancer.

[19]  J. Kwong,et al.  High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. , 2001, Cancer research.

[20]  W. Yeo,et al.  Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[22]  Yucai Wang,et al.  Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. , 2007, Lung cancer.

[23]  Chien-Jen Chen,et al.  High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1–DNA adduct levels in human hepatocellular carcinoma , 2002, Molecular carcinogenesis.

[24]  W. Tsai,et al.  Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA , 2007, Clinical Cancer Research.

[25]  F. Latif,et al.  Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. , 2005, Cancer research.

[26]  M. Uribe,et al.  Hepatocellular carcinoma. An overview. , 2006, Annals of hepatology.

[27]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Bacik,et al.  Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors , 2004, Molecular Cancer.

[29]  W. Yeo,et al.  Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  H. Donninger,et al.  The RASSF1A tumor suppressor , 2007, Journal of Cell Science.

[31]  J. Minna,et al.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  G. Pfeifer,et al.  Frequent hypermethylation of the RASSF1A gene in prostate cancer , 2002, Oncogene.

[33]  N. Nishida,et al.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.

[34]  A. Heim,et al.  Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. , 2007, Human molecular genetics.

[35]  M. Widschwendter,et al.  DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.

[36]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[37]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. , 2001, Cancer research.

[38]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. , 2001, Cancer research.

[39]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[40]  Chien-Jen Chen,et al.  Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. , 2005, Cancer letters.

[41]  G. Pfeifer,et al.  Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas , 2001, International journal of cancer.

[42]  R. Schulte‐Hermann,et al.  NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. , 2006, Journal of hepatology.

[43]  X. Qian,et al.  RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors , 2005, Laboratory Investigation.

[44]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. , 2003, The American journal of pathology.

[45]  A. Nakao,et al.  Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  G. Pfeifer,et al.  Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. , 2002, Cancer research.